Opinion

Video

Long-Term Follow-Up from CheckMate 214 in Advanced RCC

The expert panel discusses the 8-year follow-up data from CheckMate 214 looking at nivolumab plus ipilimumab in first-line advanced RCC and provide clinical insights on treatment decisions.

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.
Minoo Battiwalla, MD, MS
David Rimm, MD, PhD